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Abstract: 
Sarcopenia of age is prevalent, costly, but currently lacks proven pharmacological interventions. The 
pathophysiology of sarcopenia is incompletely understood, but appears to involve multiple pathways 
including inflammation, hormonal dysregulation, impaired regeneration, mitochondrial dysfunction 
and denervation. There are several ways that we might select potential pharmacological interventions 
for testing in clinical trials. These include a ‘bottom up’ approach using basic science to elucidate the 
molecular processes involved and identifying potential targets from this knowledge – a strategy that 
has led to the development of myostatin inhibitors. A ‘top down’ approach might use observational 
data to examine the association between physical function and use of certain medications, such as 
the association of angiotensin converting enzyme inhibitors with slower decline in physical function.. 
 Once a pharmacological intervention has been proposed, efficacy must be demonstrated in this 
complex multi-morbid population. Both muscle mass and muscle function need to be measured as 
outcomes, but these outcomes require large sample sizes and sufficient follow-up to detect change. 
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Biomarkers that can predict the response of sarcopenia to intervention after a short time would 
greatly assist our ability to select candidate interventions in short proof of concept trials. Further 
development of trial methods is required to accelerate progress in this important area of medicine for 
older people. 
 
Key points: 
-Sarcopenia is prevalent and costly but lacks effective pharmacological treatments 
-Pharmacological interventions could be selected by ‘bottom up’, ‘top down’ or combination 
approaches 
-A tiered approach to outcomes measurement is needed, with the development of biomarkers that 
predict longer-term outcomes 
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Selecting potential pharmacological interventions in sarcopenia 
1. Introduction 
The term sarcopenia is derived from the Greek words for ‘poverty’ and ‘flesh’ and was first used in 
1989 to describe age-related loss of muscle mass [1]. Sarcopenia is associated with poor current and 
future health [2] with increased risk of physical disability, falls, poor quality of life and admission to 
hospital and care homes [3] as well as increasing theincreased risk of fragility fracture [4]. It is also 
costly; the estimated direct healthcare cost attributable to sarcopenia in 2000 in the USA was 
$US£18.5 billion [5] and this is only set to increase.  
Sarcopenia remains largely undiagnosed and undertreated because of difficulties with a universally 
accepted definition, requirement for equipment to measure muscle mass and dispute regarding which 
outcomes would best indicate treatment efficacy [6]. However, agreement has emerged that low 
muscle mass alone provides is of insufficient clinical relevance if not combined with muscle weakness 
and/or functional impairment [7]. The European Working Group on Sarcopenia in Older People 
(EWGSOP) consensus conference in 2010 proposed a diagnosis based on low muscle mass 
(appendicular lean mass/height2) with either low muscle strength (grip strength) or low physical 
performance (gait speed) [8]. Similar guidelines have emerged from other bodies including in the USA 
[9], however, the diagnostic criteria for sarcopenia continue to evolve as our understanding of the 
epidemiology and pathophysiology continue to improve. 
Sarcopenia is prevalent in older people; it occurs in at least 1 in 20 community-dwelling individuals 
and up to 1 in 3 frail older people living in nursing homes, and prevalence increases with age [10]. 
There is a clear need for intervention in sarcopenia; however, the best way to identify candidate 
interventions and choose which to progress into clinical trials and clinical application is less clear. This 
paper will review two main aspects of pharmacological intervention in sarcopenia. Firstly, we consider 
the ways in which candidate pharmacological interventions might be selected for testing in clinical 
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trials. Secondly, we discuss what criteria might need to be met to deem a pharmacological 
intervention as successful and the various different outcome data that might therefore be required.  
2. Pathophysiology of sarcopenia 
Multiple physiological pathways contribute to the maintenance of muscle mass and function. These 
affect cellular function, turnover, growth, repair and the net balance of protein synthesis and 
degradation [11]. Loss of muscle mass can therefore occur from alterations in multiple interacting 
pathways. It is therefore possible that there may be several different subtypes of sarcopenia 
associated with different pathways. Key pathways thought to be involved in muscle tissue metabolism 
[12] are demonstrated in Figure 1. A comprehensive account of the pathophysiology of sarcopenia is 
beyond the scope of this article, but Figure 1 serves to illustrate the complex biology of the condition. 
3. Selection of Pharmacological Intervention 
3.1 What does an ideal intervention look like? 
An ideal pharmacological intervention would be effective in all cases of sarcopenia, no matter what 
the causative pathology, and would ideally be effective at treating other diseases of old age to avoid 
exacerbating the problem of polypharmacy. It should be inexpensive, orally administered with an 
acceptable frequency of administration to aid adherence, and should have  a low risk of causing side 
effects.  
 
 
There are various means by which pharmacological interventions could be selected for testing in trials 
against sarcopenia. These include ‘top down’ approaches through the use of observational data or 
reviewing the off-target effects of existing drugs.a ‘bottom up’ approach using insights from basic 
biology or ‘omics’ techniques to select pharmacological targets. They also include a ‘bottom up’ 
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approach using insights from basic biology or ‘omics’ techniques to select pharmacological targets ‘top 
down’ approaches through the use of observational data or reviewing the off-target effects of existing 
drugs. These are summarised in Figure 2. 
3.2 Top down approaches 
Employing observational studies to examine the association between physical function and 
medication use in routine clinical practice is a fruitful approach to target identification. Such 
approaches have demonstrated that angiotensin converting enzyme (ACE) inhibitors are associated 
with slower decline in muscle mass, muscle strength and walking speed [13] [14]. Knowledge of the 
interaction of angiotensin at a cellular level in muscle (inhibition of insulin-like growth factor-1 (IGF-1) 
action) as well as stimulation of nuclear factor kappa-light-chain-enhancer of activated B cells  (NFκKβ) 
and tumour necrosis factor α (TNFα)) has since provided supportive evidence for this interaction. 
Observational studies have also demonstrated that people with better higher level of anti-oxidants 
status have better physical function [15]. This finding accords with insights from basic biology given 
elevated levels of reactive oxygen species and pro-inflammatory cytokines are found in many 
conditions when muscle wasting is present where low muscle mass is found and are thought to 
activate NFκβNFKβ or the ubiquitin proteasome system via muscle RING-finger protein-1 (MuRF-1) 
resulting in protein degradation [12]. Allopurinol, an inhibitor of xanthine oxidase that is known to 
reduce oxidative stress across a range of diseases including vascular disease [16], has been associated 
with improved functional outcomes in patients undergoing rehabilitation [17] again suggesting that 
agents that reduce oxidative stress are worth testing in patients with sarcopenia. 
 
Other agents have been noted to have positive associations with muscle function, but biological 
plausibility is either lacking or suggests anthe findings suggest our incomplete understanding of 
biological pathways. An example here is statin use, which has been associated with greater proximal 
muscle strength in community dwelling individuals [18] [19]. This is despite the known phenomenon 
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of statin induced myopathy. Observational studies have also revealed adverse associations with 
function, for example, furosemide with the use of furosemide and calcium channel blockers [20]. 
Whilst such adverse findings might appear less useful at first glance, such data may help practitioners 
to avoid making sarcopenia worse, and might also suggest new avenues to explore in terms of 
underlying mechanisms that lead to sarcopenia. 
 
3.3 Bottom up approaches 
A ‘bottom up approach’ starts with the molecular processes involved in muscle atrophy and 
sarcopenia and identifies potential targets from this knowledge. Such an approach has revealed that 
myostatin (a member of the transforming growth factor β (TGFβ ) superfamily) plays a crucial role in 
muscle growth via interaction with the activin receptor [6]. Myostatin negatively regulates muscle 
growth via inhibition of the Phosphoinositide 3 Kinase/Protein kinase B (PI3K/AKT) pathway and 
reduction of the levels of myogenic regulatory factors [12]. Myostatin is inhibited by a protein called 
follistatin.  
Myostatin inhibition is required for muscle growth and development [6] and levels of myostatin have 
been observed to be increased in conditions with similarities to sarcopenia, such as heart failure and 
AIDS-related cachexia [21]. Pharmacological manipulation of myostatin has therefore become a key 
research target in sarcopenia [22]. Several different approaches have been taken to this including 
myostatin blocking antibodies, myostatin propeptide, follistatin, follistatin related proteins, soluble 
myostatin receptors, small interfering RNA and small chemical inhibitors [22]. Several agents have 
now made it through to clinical trials, for example, Athe humanised monoclonal antibody to 
myostatin, LY2495655. A multi-centre randomised controlled trial in 2015 of LY2495655 in older 
people with recent falls and low muscle strength met its primary endpoint of increased appendicular 
lean mass at 24 weeks. It also improved fast gait speed, stair climbing time and chair rise with arms 
but not other functional measures., has recently been demonstrated in a multi-centre randomised 
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controlled trial to increase appendicular lean mass and improve some measures of muscle function in 
older people with recent falls and low muscle strength [23]. 
 
Ultimately a long term imbalance between rate of protein synthesis and breakdown is thought to have 
the potential to exacerbate age-related loss of muscle tissue [12] due to reduced total and essential 
amino acid intake as well as altered anabolic-catabolic balance. Branched chain amino acids, such as 
leucine, have been demonstrated to boost pathways leading to increased protein translation [2]. 
However, older skeletal muscle has been noted to have significant anabolic resistance to protein 
nutrition during immobilisation [24] and this has led to the suggestion that recommendations for 
protein intake should be increased for older people [2]. 
 
Approaches altering downstream effects in favour of anabolism are likely therefore to need to be used 
in addition to nutritional supplementation. For example, the manipulation of myostatin represents an 
approach where a conserved signalling pathway has been reviewed [11] and manipulated. Several 
generic pathway points have been considered with respect to sarcopenia such as caspase inhibitors 
or proteasome inhibitors [6]. However, many of these would be involved in the cellular transcription 
pathway more generally and may have widespread effects, including the potential for promotion of 
cancerous changes. 
 
It is likely that new targets and treatment strategies will emerge as the pathways involved in 
sarcopenia are elucidated through reviews of gene expression patterns and more information Is 
gained through metabolomics and proteomics [25] [26]. The Frailomic initiative is collecting urine and 
blood biomarkers in 75,000 participants who will be stratified as frail or not frail according to Fried’s 
criteria [27]. Over 70% of the participants are over 65 years old [27]. The challenge of this approach 
will be the volume of information, and the massive task of translating this information into the 
development of new pharmacological agents. The clinical trials involved will be in a complex 
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population with multiple diseases that contribute to physical, cognitive and functional disability. This 
large variability will increase the difficulty of detecting both treatment effects and adverse effects [7]. 
The fact that currently used drugs have a better known side-effect profileIt is the known side effect 
profile that potentially providesprovides  another further advantage to their reappropriation and may 
pave the way for further ‘new tricks for old drugs’ [2].  
 
The number of potential biological targets is likely to be far higher than the number of existing drugs 
that could be repurposed. There is therefore a limit to what observational data can tell us about target 
selection, and some way of refining our ability to select from the large number of targets suggested 
by basic biology will be needed. If a specific target or biomarker can be developed then it may be that 
action on these new targets could be screened for using high throughput drug screening, using both 
marketed drugs and those from compound libraries. Developing robust, validated preclinical models 
is therefore essential if we are to effectively screen large numbers of candidate molecules, but this 
task is made more complex by the large number of biological pathways involved in the genesis of 
sarcopenia. 
4. Outcome measures 
The history of the development of osteoporosis diagnosis and treatment reveals interesting parallels 
with the field of sarcopenia. Little progress was made in developing effective treatments for 
osteoporosis until a set of diagnostic criteria were agreed; the development of effective treatments 
then helped to establish these diagnostic criteria in clinical practice. One of the main issues with 
sarcopenia research and treatment has been the lack of an established core outcome set [28]. In 
health it appears that there is a relatively strong correlation between muscle mass and strength, 
however, the assumption that an increase in muscle mass will be associated with an increase in 
function does not always hold [11]. In general there is a ‘hierarchy of response’ to any given 
intervention [11]. For example, in response to resistance training in older people a large effect may be 
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seen in quadriceps strength but this may not translate into improved physical function [29]. Similarly, 
interventions might increase muscle mass, but not necessarily muscle strength; a situation seen in 
short-term trials of myostatin inhibitors [30]. The difficulty in selecting pharmacological interventions 
is therefore exacerbated by the difficulty in deciding how to declare an intervention successful. 
 
4.1 Progression of candidate interventions through trial stages 
Different outcome measures may be of use at different trial phases. For example, early phase 
outcomes need to be highly responsive (so as to minimise sample size) but should correlate with later 
trial outcomes. Such outcomes might reflect molecular and cellular changes in muscle without 
necessarily reflecting whole body function. Middle phase outcomes should reflect physical function 
and again need to correlate with later phase outcomes; a failure of such outcomes to predict late-
phase trial success renders any middle-phase results of little value. Late phase outcomes need to 
reflect what is important to individual patients, health services and society as a whole. Again, parallels 
can be drawn with osteoporosis, where bone turnover markers, bone mineral density and fractures 
form key outcomes from early, middle and late phase trials. Potential early, mid and late phase 
outcomes for sarcopenia trials are suggested in Table 1. 
4.2 Early Phase Outcomes 
4.2.1 Biomarkers 
Biomarkers are objectively measurable indicators of biological or pathological processes, and have the 
potential to be used as markers of response to a therapeutic intervention [31]. Measuring changes in 
physical function and muscle mass in sarcopenia requires sufficient time for measurable changes to 
occur (typically months), and because of the variability of these measures, sample sizes of typically 
50-150 per arm are required. Reliable, responsive, easy to measure biomarkers for the detection and 
monitoring of sarcopenia could allow smaller, more rapid proof of concept trials of pharmacological 
interventions [26]. Field Code Changed
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Numerous biomarkers have been proposed [26] but are often not specific to sarcopenia [25].  Type III 
collagen is a subtype of collagen found in skeletal muscles. During its synthesis from procollagen III 
the N-terminal propeptide (P3NP) is cleaved and released into the circulation in direct proportion to 
type III synthesis and is therefore a measure of tissue remodelling [32]. In a cross-sectional study 
plasma concentrations of P3NP were found to be inversely related to total and appendicular lean mass 
in postmenopausal women but not in older men. [33]. 
 
C-terminal agrin fragment (CAF) is another proposed biomarker. During neuromuscular remodeling 
agrin is cleaved by neurotrypsin releasing CAF which is detectable in plasma. Increases in serum CAF 
have been associated with neuromuscular junction disruption, muscle fibre atrophy and dysfunction 
[26] and have been reported to be elevated in older adults with sarcopenia compared with age 
matched controls [32]. In a trial of 23 older adults women had a higher baseline circulating CAF than 
men and the level increased by 10.4% after 6 weeks of resistance training. This increase was correlated 
with significant changes of cross sectional area of vastus lateralis (p=0.008)In men serum CAF 
concentrations have been reported to be inversely related to appendicular lean mass but no 
significant relationship was observed in women [32]. A study in 2013 looked at CAF levels in patients 
admitted acutely with hip fractures and found that serum levels were significantly higher(p<0.001) in 
all patients with sarcopenia (diagnosed using EWGSOP definition) at 172.2pM in sarcopenic patients 
and 93.0pM in non-sarcopenic patients [34]. This suggests that CAF levels may be of relevance in both 
community dwelling and hospitalised patients with sarcopenia.  
 
It may be that biomarkers such as P3NP and CAF have a role in helping to identify sarcopenia subtypes, 
but considerable work is needed to establish whether these biomarkers can predict response of 
muscle to interventions, and hence whether they are valid measures for use in trials. It is probable 
that given the multiple pathways involved in the pathogenesis of sarcopenia, a panel of biomarkers 
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will need to be measured, so that responses in a particular pathway affected by a candidate 
intervention are not missed.  
 
4.3 Middle Phase Outcomes 
4.3.1 Muscle mass 
Assessment of muscle mass can be made using Dual energy X-ray aAbsorptiometry (DXA), cComputed 
tTomography (CT) or mMagnetic rResonance iImaging (MRI) [35]. CT and MRI scanning in particular 
have been used widely in oncology studies looking atassessing the impact of sarcopenia [36]. 
Bioelectrical impedance analysis can also be used to predict lean muscle mass; results depend on the 
instrument used, the conversion equation employed, and are also subject to variation depending on 
peripheral oedema and hydration status [37]. Bioimpedance is quick and easy to perform however 
and undoubtedly has a key role in screening for sarcopenia, although it is not the preferred technique 
for measuring muscle mass change in trials. A non-radiological method to assess skeletal muscle mass 
has been validated. This is based on D3-creatine dilution from an oral dose and detection of urinary 
creatinine enrichment by isotope ratio mass spectrometry. This has been used in longitudinal 
assessment of changes in skeletal muscle mass [38], and reportedly has the potential to be superior 
to DXA [26]. However, it requires specialist techniques that are likely to have limited availability [26]. 
4.3.2 Functional measures including muscle strength 
Because tThe definition of sarcopenia encompasses both muscle mass and muscle function, it is 
therefore essential to include measurement of muscle function in any suite of sarcopenia outcomes. 
Isometric hand grip has been widely used as a general indicator of functional status [39], as have 
measures of lower limb extremity strength such as leg press strength and isokinetic leg extension 
strength [39]. These measures evaluate muscle function directly, and thus provide insight into 
physiology. They do not always reflect the way that muscle is used in daily life however, and some 
measures (e.g. grip strength) may not be responsive to interventions. Other measures examine muscle 
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function at a whole body level; for example, the time to walk 400 metres [39], six minute walking 
distance [40], gait speed (usually over a 3 or 4 metre course) and timed up and go test [41]. These 
measures better reflect how muscles are used in activities of daily living, but many are composites of 
muscle, nerve and cardiorespiratory function, which may dilute the impact of muscle-specific 
intervention effects. 
 
4.3.3 Composite measures of function 
The Short Physical Performance Battery (SPPB) is a widely used composite measure of lower extremity 
function [42] that has been validated and shown to be responsive to intervention [43] and associated 
with a clinically meaningful change [35]. It consists of measures of walking, balance and sit to stand 
[43] and has been shown to correlate with quality of life [44]. There are perhaps more data linking the 
SPPB with relevant outcomes such as death, hospitalisation, future dependency and falls than for any 
other functional measure; the SPPB is also easy to perform. It is therefore emerging as one of the 
functional measures of choice in sarcopenia trials and is under consideration as a surrogate marker of 
efficacy for future sarcopenia drug licensing. 
 
4.3.4 Activities of Daily Living and Quality of Life measures 
Alteration in Qquestionnaires looking atthat assess quality of life, functional status and psychological 
state are also potential outcome measures [42]. These can either be generic questionnaires or specific 
to sarcopenia, for examples, SarQOL is a quality of life measure that aims to be more specific to 
sarcopenia with seven main domains [45] and has recently been validated in English [46]. It is, 
however, yet to be validated.  
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4.4 Late Outcomes 
These outcomes are much less specific in terms of alteration in muscular function but represent 
outcomes that will be of greatest importance to patients and health and social care funders. Late 
outcomes might include measures such as number of falls, hospital admissions, need for care 
assistance or risk of institutionalisation [35]. 
 
Given the likely heterogeneity of both individuals and pathophysiological subtypes of sarcopenia, the 
inspection of single variables will inevitably result in a partial and incorrect picture. Multiplex analyses 
are gaining increasing plausibility with the development of ‘omics’ techniques and this approach may 
well be of increasing importance in an approach to biomarkers of sarcopenia. These analyses involve 
complex statistics but might potentially allow the early detection of subclinical syndromes as well as 
aiding clinical diagnosis and monitoring of response to treatment [26]. The downside of such methods 
is that the multivariate nature of such analyses will likely require relatively large numbers of patients. 
Any use of biomarkers to predict response to interventions in sarcopenia is limited by the lack of data 
on efficacious interventions – it is necessary to demonstrate that an intervention improves sarcopenia 
before one can tell if changes in a biomarker for sarcopenia predict improvements in sarcopenia itself.  
 
5. Conclusion 
Sarcopenia is not currently routinely diagnosed in clinical practice. It is unlikely that this will become 
the case until a proven benefit of intervention can be established. Studies have taken place for many 
years looking at exercise interventions as well as nutritional supplementation in sarcopenia. 
Resistance training remains the key intervention proven to improve muscle function and physical 
performance in patients with sarcopenia. Nutritional and some pharmacological interventions may 
only be of benefit when combined with exercise training, however, exercise interventions may not 
necessarily add benefit to all pharmacological interventions.  
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Exercise interventions in sarcopenia are likely only to be applicable to a limited proportion of the 
population given their baseline functional status. Ideal agents might mimic exercise as an intervention, 
perhaps by acting on the same physiological pathways and thus would not need to be combined with 
exercise and be of benefit in those patients who can not or will not exercise. For example, a trial 
looking at 130 older patients with functional impairment found that the group supplemented with 
perindopril had an improvement in exercise capacity equivalent to that reported after six months of 
exercise training [47]. A further trial demonstrated that perindopril did not enhance the effect of 
exercise training on physical function providing further support that the effects of exercise and 
pharmacological intervention in this case are not additive [48].   
Pharmacological intervention in sarcopenia is therefore an extremely topical and relevant avenue in 
sarcopenia treatment. The best way to select pharmacological interventions for trials is likely to be a 
combination of the top down and bottom up approaches, acting in a complementary fashion. Further 
work is required to define the optimum set of outcome measures used in early, middle and late-phase 
trials; outcomes will need to be multidimensional to ensure that success is defined not just by 
improvements in pathology and physiology, but in terms of patient-centred outcomes - improvement 
in function and increased independence. Future trials need to place these outcomes centre-stage if 
patients and clinicians are to be convinced of the benefits of pharmacological interventions for 
sarcopenia. 
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Figure 1 – Some key cellular pathways involved in muscle tissue signalling and 
metabolism 
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Figure 2 – Approaches to selection of pharmacological intervention 
 
 
Table 1 – Potential trial outcomes in sarcopenia 
 
Trial Phase Potential outcome measure Parallel with osteoporosis trials 
Early Biomarkers of muscle pathophysiology Bone turnover markers 
Middle Short Physical Performance Battery 
Walking speed 
Muscle mass (DEXA, CT, BIA) 
Muscle strength 
Quality of Llife measures 
Activities of dDaily Lliving 
Bone mineral density 
Late Falls 
Institutionalisation 
Hospitalisation 
Quality of Life measures 
Fractures 
 
DXA – Dual energy X-ray absorptiometry 
Formatted: Left
Formatted: Left
Formatted: Left
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CT – computerised tomography 
BIA – Bioelectrical impedance analysis 
